赛托生物
(300583)
| 流通市值：28.69亿 | | | 总市值：29.35亿 |
| 流通股本：1.85亿 | | | 总股本：1.90亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 351,284,155.1 | 238,490,756.82 | 284,575,520.5 | 410,642,497.52 |
| 应收票据及应收账款 | 271,654,095 | 272,117,151.74 | 196,931,778.08 | 247,850,788.82 |
| 应收账款 | 271,654,095 | 272,117,151.74 | 196,931,778.08 | 247,850,788.82 |
| 应收款项融资 | 146,032,897.43 | 111,080,353.54 | 59,680,889.32 | 143,273,703.85 |
| 预付款项 | 7,217,645.98 | 5,367,236.48 | 22,732,644.76 | 7,758,859.21 |
| 其他应收款合计 | 24,400,751.55 | 22,731,965.72 | 14,850,655.4 | 11,332,382.77 |
| 存货 | 730,067,778.48 | 722,624,129.92 | 846,749,036.69 | 776,035,531 |
| 其他流动资产 | 21,748,620.43 | 25,375,111.39 | 29,956,520.75 | 28,952,526.11 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,552,405,943.97 | 1,397,786,705.61 | 1,455,477,045.5 | 1,625,846,289.28 |
| 非流动资产: | | | | |
| 长期股权投资 | 67,022,673.3 | 65,119,540.6 | 64,834,353.59 | 68,262,515.27 |
| 固定资产 | 1,227,569,958.97 | 1,266,998,561.61 | 1,258,086,258.94 | 1,278,568,680.82 |
| 在建工程 | 300,171,159.41 | 279,287,721.36 | 305,567,500.17 | 302,019,111.64 |
| 使用权资产 | 8,924,749.91 | 9,627,309.04 | 9,628,920.68 | 10,683,173.32 |
| 无形资产 | 197,459,899.44 | 200,581,837.81 | 198,892,823.81 | 198,552,111.67 |
| 长期待摊费用 | 1,171,920.78 | 1,300,581.93 | 1,346,942.21 | 1,471,621.07 |
| 递延所得税资产 | 6,858,885.63 | 11,265,195.76 | 11,751,326.6 | 13,403,251.36 |
| 其他非流动资产 | 8,502,227.38 | 8,274,950.12 | 4,712,792.45 | 7,300,209.4 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,817,681,474.82 | 1,842,455,698.23 | 1,854,820,918.45 | 1,880,260,674.55 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 3,370,087,418.79 | 3,240,242,403.84 | 3,310,297,963.95 | 3,506,106,963.83 |
| 流动负债: | | | | |
| 短期借款 | 761,781,519.39 | 627,006,377.49 | 611,176,840 | 701,218,946.47 |
| 应付票据及应付账款 | 293,969,203.86 | 246,821,029.54 | 307,661,689.63 | 418,272,004.43 |
| 其中：应付票据 | 98,488,853.06 | 54,209,766.03 | 92,853,592.45 | 154,485,344.85 |
| 应付账款 | 195,480,350.8 | 192,611,263.51 | 214,808,097.18 | 263,786,659.58 |
| 合同负债 | 5,616,773.46 | 5,577,858.63 | 10,074,618.82 | 15,711,758.84 |
| 应付职工薪酬 | 20,504,655.85 | 22,306,901.88 | 21,657,573.71 | 23,673,223.51 |
| 应交税费 | 12,292,200.63 | 16,121,790.4 | 11,558,801.37 | 14,800,993.44 |
| 其他应付款合计 | 30,382,321.05 | 19,536,474.35 | 41,258,947.09 | 52,101,435.37 |
| 一年内到期的非流动负债 | 27,395,954.89 | 48,979,778.5 | 48,506,804.84 | 39,082,523.24 |
| 其他流动负债 | 301,840.46 | 409,081.08 | 633,372.01 | 857,101.09 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 1,152,244,469.59 | 986,759,291.87 | 1,052,528,647.47 | 1,265,717,986.39 |
| 非流动负债: | | | | |
| 长期借款 | 72,817,119.34 | 108,340,829.15 | 136,739,365.17 | 118,881,595.19 |
| 租赁负债 | 6,948,546.77 | 7,256,437.32 | 7,251,984.24 | 7,655,340.21 |
| 长期应付款 | 43,459,151.22 | 47,123,081.78 | - | - |
| 递延收益 | 23,741,971.3 | 24,547,500.9 | 25,353,030.5 | 26,158,560.1 |
| 递延所得税负债 | 731,684.63 | 768,691.61 | 3,093,608.25 | 3,216,379.73 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 147,698,473.26 | 188,036,540.76 | 172,437,988.16 | 155,911,875.23 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,299,942,942.85 | 1,174,795,832.63 | 1,224,966,635.63 | 1,421,629,861.62 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 189,702,126 | 189,702,126 | 189,702,126 | 118,563,829 |
| 资本公积 | 1,276,956,870.47 | 1,276,956,870.47 | 1,276,889,758.87 | 1,348,095,167.47 |
| 其他综合收益 | -205,389.28 | -1,097,419.76 | -474,364.53 | -375,865.67 |
| 盈余公积 | 93,766,209.97 | 93,766,209.97 | 87,727,115.4 | 87,727,115.4 |
| 未分配利润 | 455,899,751.21 | 452,829,022.56 | 474,421,600.57 | 473,231,707.63 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,016,119,568.37 | 2,012,156,809.24 | 2,028,266,236.31 | 2,027,241,953.83 |
| 少数股东权益 | 54,024,907.57 | 53,289,761.97 | 57,065,092.01 | 57,235,148.38 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,070,144,475.94 | 2,065,446,571.21 | 2,085,331,328.32 | 2,084,477,102.21 |
| 负债和股东权益合计 | 3,370,087,418.79 | 3,240,242,403.84 | 3,310,297,963.95 | 3,506,106,963.83 |
| 公告日期 | 2024-04-29 | 2024-04-29 | 2023-10-21 | 2023-07-31 |
| 审计意见(境内) | | 标准无保留意见 | | 标准无保留意见 |